10 June 2025 · Patients with mitochondrial variants have an increased risk of deafness with amikacin, gentamicin, neomycin and tobramycin. Guidance on testing is provided.
11 August 2022 · Amikacin products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration